Tango Therapeutics
TNGXTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing the next generation of precision oncology therapies.
Earnings
Next report
Aug 4, 2026 (In 6 days)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing the next generation of precision oncology therapies. The company utilizes a proprietary target discovery platform based on the principle of synthetic lethality to identify and treat cancers with specific genetic alterations. Its core value proposition lies in developing small molecules that selectively kill cancer cells while sparing healthy tissue, addressing high unmet medical needs in defined patient populations.
Tango is a pioneer in synthetic lethality, positioning itself as a developer of potentially best-in-class MTA-cooperative PRMT5 inhibitors and first-in-class CoREST inhibitors.
Questions, answered.
- What is Tango Therapeutics's market cap?
- Tango Therapeutics (TNGX) has a market capitalization of $4.4B and trades on NASDAQ.
- What is Tango Therapeutics's revenue and profitability?
- Tango Therapeutics generated $57.0M in trailing twelve-month revenue with a net loss of $107.2M, representing a net margin of -188.2%, with free cash flow of -$142.5M. These figures are based on the Q1 2026 filing.
- Who are Tango Therapeutics's competitors?
- Tango Therapeutics's key competitors include IDEAYA Biosciences, Amgen, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Tango Therapeutics partner with?
- Tango Therapeutics's notable partners include Revolution Medicines, Inc., Erasca, Inc., Eli Lilly and Company.
- Where is Tango Therapeutics headquartered?
- Tango Therapeutics is headquartered in United States of America and employs approximately 140 people. It has been publicly traded since 2021.
